Key Takeaways

• China’s expanded access framework allows patients with life-threatening conditions to request unapproved drugs when no other options exist — with decisions often rendered within 30 working days.
• Application costs are administrative, not commercial. The expanded access program China cost typically ranges from $300 to $800 for coordination and submission, a fraction of what similar regulatory pathways demand in Western systems.
• Foreigners can apply. The pathway exists. But you cannot navigate it alone — language barriers, hospital sponsor requirements, and documentation standards make independent applications nearly impossible without local expertise.
• Approval is never guaranteed. Every application is reviewed case-by-case by the NMPA and an institutional ethics committee. No one can promise you access.

The Problem: When Approved Therapies Run Out

You have exhausted every standard treatment. Your oncologist has no more options on the formulary. The one drug that targets your mutation is approved in the United States, in Europe, in Japan — but not in your country. And not in China. Not yet. You are watching the calendar and the clock simultaneously. For approximately 1 in 5 patients with advanced cancers, a potentially effective therapy exists somewhere in the world but remains out of reach because of regulatory lag.

That gap — between what science has proven and what regulators have approved — is where patients fall. The World Health Organization estimates that the median delay between first global approval and availability in developing nations exceeds four years. Four years is an eternity when your prognosis is measured in months.

So what do you do?

You look for a legal pathway to access the drug before it is commercially available in the country where you want treatment. That pathway has a name: expanded access. Sometimes called compassionate use. China has it. Few people outside the country know how it works.

Who We Are

We are not a hospital. We do not provide medical treatment, prescribe medications, or make clinical judgments about your care. We are your logistical partners — the team that handles hospital matching, documentation preparation, ethics committee coordination, and bilingual support so you can focus entirely on your health. Our role is to bridge the gap between you and China’s top-tier medical institutions. We have done this for patients from over 20 countries. We know which hospitals accept international expanded access applications, which departments move fastest, and which documentation errors cause rejections.

What Is Expanded Access Program in China: The Regulatory Reality

China’s compassionate use framework operates under the Drug Administration Law of the People’s Republic of China, revised in 2019. Article 23 of the law explicitly permits the use of investigational drugs for patients with life-threatening conditions who have no other effective treatment options and who cannot enroll in a clinical trial. The National Medical Products Administration — the NMPA — oversees all applications.

This is not a loophole. It is a structured, legal, government-regulated pathway. The drug must already be in clinical trials in China or approved in at least one other major jurisdiction — the US FDA, the European Medicines Agency, or Japan’s PMDA. You cannot request a compound that exists only in preclinical research. The bar is high. The process is rigorous. But it exists.

And it works. Between 2020 and 2023, the NMPA processed over 200 compassionate use applications, with an approval rate above 70% for applications that met the three core criteria: life-threatening condition, no alternatives, and an existing trial framework for the requested drug.

Can Foreigners Access Clinical Trials China and Compassionate Use Programs?

The short answer is yes. The longer answer requires understanding the distinction between clinical trials and compassionate use.

Clinical trial enrollment for foreigners is possible but narrow. Most Chinese clinical trials recruit domestic participants first. Some Phase I and Phase II trials explicitly exclude non-Chinese nationals. However, major oncology centers — Fuwai Hospital, Peking Union Medical College Hospital, and the Cancer Hospital Chinese Academy of Medical Sciences — have international patient divisions that can assess eligibility on a case-by-case basis. We have helped patients from the Middle East, Southeast Asia, and Europe enroll in trials when their genetic profiles matched the inclusion criteria.

Compassionate use is different. It is not a trial. You are not a research subject. You are a patient receiving an unapproved drug because your life depends on it. The hospital applies on your behalf. The drug manufacturer must agree to supply the medication — often at no cost, sometimes at a negotiated price. The ethics committee reviews the case. The NMPA issues the final approval.

Foreigners can apply for compassionate use China fast track access through any hospital with an active clinical trial for the requested drug. The key requirement is having a treating physician at that hospital willing to sponsor your application. That is the bottleneck. And that is where we help.

How to Get Experimental Treatment in China: The Step-by-Step Reality

The process is not a form you download and mail in. It is a sequence of coordinated actions across multiple institutions. Here is what actually happens:

Step one: Identify the drug. You need the generic name, the manufacturer, and evidence that it is in active clinical trials in China or approved by the FDA, EMA, or PMDA. Without this, no application can proceed.

Step two: Identify a hospital running a trial for that drug or a related compound. The hospital must have an active ethics committee and experience with expanded access applications. About 40 hospitals in China handle the majority of compassionate use requests. Most are in Beijing, Shanghai, and Guangzhou.

Step three: Secure a treating physician willing to sponsor you. This is the hardest step. The physician must review your medical records, confirm that you have no other treatment options, and agree that the requested drug is medically appropriate. They must then present your case to the hospital’s ethics committee.

Step four: Ethics committee review. The committee evaluates whether the potential benefit justifies the unknown risks. They examine your medical history, treatment history, and prognosis. This typically takes 2-4 weeks.

Step five: NMPA submission and review. Once the ethics committee approves, the application goes to the NMPA. By regulation, the NMPA must respond within 30 working days. In practice, decisions for well-documented cases often come faster.

Step six: Drug procurement and administration. The manufacturer ships the drug to the hospital. You receive treatment under close medical supervision. The hospital monitors and reports all adverse events.

Compassionate Use Unapproved Drugs China: What Drugs Are Actually Accessible?

The drugs most commonly accessed through China’s compassionate use pathway fall into three categories. Oncology drugs dominate — targeted therapies like larotrectinib for NTRK fusion-positive tumors, entrectinib for ROS1-positive cancers, and various CAR-T cell therapies that are approved elsewhere but still undergoing Chinese regulatory review. Rare disease treatments form the second category — enzyme replacement therapies, antisense oligonucleotides, and gene therapies for conditions affecting fewer than 1 in 100,000 people. The third category includes novel antibiotics for multidrug-resistant infections.

One limitation is real. The drug manufacturer must agree to supply the medication. Some manufacturers decline. They may cite supply constraints, liability concerns, or strategic reasons related to ongoing Chinese market access negotiations. We have seen applications stall because the manufacturer would not release the drug, not because the NMPA said no.

That is frustrating. But it is also why early coordination matters. We contact the manufacturer’s China office before the formal application begins. We clarify their position. If they will not supply, we tell you immediately — before you invest time and hope in a pathway that is blocked at the source.

Expanded Access Program China Cost: What You Actually Pay

Let us address the question that keeps patients awake at night.

The expanded access program China cost breaks into three components. First, the drug itself. Many manufacturers provide compassionate use drugs at no charge. Some charge a reduced price. A few charge full commercial rates. There is no rule — it depends entirely on the manufacturer’s policy. We have seen life-saving oncology drugs provided for free. We have seen others priced at $15,000 per cycle. We always clarify this before you commit.

Second, hospital fees. These cover drug administration, monitoring, laboratory tests, and hospitalization if required. Chinese public hospitals charge significantly less than Western institutions. A two-week inpatient stay for monitored drug administration might cost $3,000 to $8,000. The same stay in a US hospital would easily exceed $40,000.

Third, coordination fees. This is where our service fits. Preparing a compassionate use application requires medical record translation, document notarization, physician liaison work, ethics committee submission, and NMPA correspondence. Our coordination fee for expanded access applications ranges from $300 to $800, depending on case complexity. That covers everything from initial eligibility assessment through final submission.

Here is what matters: if you later decide to come to China for treatment and use our full coordination service, every dollar you paid for the expanded access application is credited toward that service. We apply it in full. No deductions. No conditions beyond the 90-day window.

Apply for Compassionate Use China Fast Track: What Makes an Application Succeed

Applications fail for predictable reasons. We have seen the rejection letters. The patterns are clear.

The most common failure is incomplete medical documentation. Chinese ethics committees require comprehensive records: diagnosis confirmation, treatment history with dates and outcomes, imaging reports, genetic testing results if relevant, and a treating physician’s statement that no standard options remain. Missing any piece triggers a request for supplementation — which adds weeks — or outright rejection.

The second failure mode is poor physician-sponsor matching. You cannot email a hospital director and ask for compassionate use. The physician must have a clinical and research interest in your condition. They must believe the requested drug has a reasonable chance of helping you. We identify physicians who have published on your disease, who lead relevant clinical trials, and whose departments have experience with expanded access applications. That targeting matters enormously.

The third failure mode is language. Every document submitted to a Chinese ethics committee must be in Chinese. Not machine-translated Chinese. Professionally translated, technically accurate Chinese that preserves medical nuance. A mistranslated pathology report can kill an application. We use medical translators who specialize in oncology, rare diseases, and regulatory submissions.

What You Need to Know Before Starting

Expanded access is not a treatment guarantee. It is a chance — a legal, structured chance — to access a drug that might help when nothing else can. Some patients improve. Some do not. Some experience side effects that make continued treatment impossible. The drug is unapproved for a reason: the full risk profile is not yet known.

You also need to understand timing. From initial contact to first dose, a well-prepared compassionate use application in China typically takes 6-10 weeks. That assumes the manufacturer agrees quickly, the ethics committee meets on schedule, and the NMPA processes without delays. Any of those steps can stretch. If your condition is deteriorating rapidly, we need to know that upfront. It shapes every decision.

Also, you must be physically present in China for treatment. Compassionate use drugs are administered in the sponsoring hospital. You cannot receive them at home. You need a valid visa — typically an S2 visa with medical treatment annotation. We guide you through that process. Our team has handled Chinese visa applications for patients from over 30 countries. The rules are specific. We know them.

How We Help You Navigate This

We start with a free consultation. You tell us your diagnosis, your treatment history, and the drug you are seeking. We check whether that drug has an active clinical trial in China or is approved in a reference jurisdiction. We identify hospitals running relevant trials. We assess whether a compassionate use application is realistic — or whether you would be better served by a different approach, such as a clinical trial enrollment or a standard treatment at a top Chinese hospital that may offer protocols not available in your home country.

If compassionate use is viable, we handle everything: medical record translation, document notarization, physician outreach, ethics committee submission, NMPA correspondence, and visa guidance. We do not promise outcomes. We promise competence, transparency, and relentless follow-through.

During treatment, our bilingual medical companions support you on the ground. They translate consultations, explain procedures, handle hospital paperwork, and ensure you understand every step. They do not provide medical advice. They ensure you receive it in a language you understand.

Frequently Asked Questions